← Eichor
Condition: Complete Remission Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Complete Remission

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · 306 location(s) · Merck Sharp & Dohme LLC · NCT06393374Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant
Phase N/A · 1 location(s) · Tongji Hospital · NCT07088354Maintenance Venetoclax in AML Fit Patients
NA · 2 location(s) · Sohag University · NCT07244367Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin'
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06761274Omission of Breast Surgery for Breast Cancer Patients With pCR on MRI and Vacuum-assisted Biopsy After NST (OPTIMIST)
NA · 1 location(s) · Seoul National University Hospital · NCT05505357Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
Phase N/A · 1 location(s) · University Hospital, Caen · NCT06045819Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Ach
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07628738Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
NA · 1 location(s) · Beijing Chao Yang Hospital · NCT04743102Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA A
Phase 3 · 1 location(s) · Fudan University · NCT05674305Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Phase 2 · 23 location(s) · Consorzio Oncotech · NCT05817903Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · 1 location(s) · Rong Tao · NCT07507318The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
Phase N/A · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06182657Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07635342Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemot
Phase 2 · 1 location(s) · Centre Henri Becquerel · NCT07593976THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT04815694Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl
Phase 2 · 34 location(s) · French Innovative Leukemia Organisation · NCT07007052Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05909293A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal C
Phase 2 · 7 location(s) · VA Office of Research and Development · NCT05563766Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07646301Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
Phase N/A · 23 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT05866458Pilot Study of Reduced Venetoclax Exposure
Phase 2 · 1 location(s) · Northwell Health · NCT07163793Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Syste
NA · 1 location(s) · N.N. Petrov National Medical Research Center of Oncology · NCT04293796Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127The Maintenance Treatment of "ITIVA" in AML Patients
NA · 1 location(s) · Henan Cancer Hospital · NCT06256627Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06949111Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast
Phase N/A · 1 location(s) · Blida 1 University · NCT07166185Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06601309Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
Phase N/A · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06451393Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With P
Phase 3 · 158 location(s) · Eastern Cooperative Oncology Group · NCT06724237
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.